Real-Time Monitoring of Cisplatin-Induced Cell Death

Since the discovery of cisplatin more than 40 years ago and its clinical introduction in the 1970s an enormous amount of research has gone into elucidating the mechanism of action of cisplatin on tumor cells. With a novel cell biosensor chip system allowing continuous monitoring of respiration, glycolysis, and impedance we followed cisplatin treatment of different cancer cell lines in real-time. Our measurements reveal a first effect on respiration, in all cisplatin treated cell lines, followed with a significant delay by interference with glycolysis in HT-29, HCT-116, HepG2, and MCF-7 cells but not in the cisplatin-resistant cell line MDA-MB-231. Most strikingly, cell death started in all cisplatin-sensitive cell lines within 8 to 11 h of treatment, indicating a clear time frame from exposure, first response to cisplatin lesions, to cell fate decision. The time points of most significant changes were selected for more detailed analysis of cisplatin response in the breast cancer cell line MCF-7. Phosphorylation of selected signal transduction mediators connected with cellular proliferation, as well as changes in gene expression, were analyzed in samples obtained directly from sensor chips at the time points when changes in glycolysis and impedance occurred. Our online cell biosensor measurements reveal for the first time the time scale of metabolic response until onset of cell death under cisplatin treatment, which is in good agreement with models of p53-mediated cell fate decision.

[1]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[2]  E. Wiltshaw,et al.  Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. , 1976, Cancer treatment reports.

[3]  Su-Jae Lee,et al.  Inhibition of AMP-activated Protein Kinase Sensitizes Cancer Cells to Cisplatin-induced Apoptosis via Hyper-induction of p53* , 2008, Journal of Biological Chemistry.

[4]  M. Atkins,et al.  GSK-3β Inhibition Enhances Sorafenib-induced Apoptosis in Melanoma Cell Lines* , 2008, Journal of Biological Chemistry.

[5]  J. Enríquez,et al.  Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels. , 2008, The Biochemical journal.

[6]  Zhongmin Guo,et al.  Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer , 2007, Journal of bioenergetics and biomembranes.

[7]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[8]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[10]  N. Holbrook,et al.  Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[11]  M. Atkins,et al.  GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. , 2008, The Journal of biological chemistry.

[12]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[13]  J. Wegener,et al.  Electric cell-substrate impedance sensing (ECIS) as a noninvasive means to monitor the kinetics of cell spreading to artificial surfaces. , 2000, Experimental cell research.

[14]  S. Wölfl,et al.  Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. , 2010, Journal of medicinal chemistry.

[15]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.

[16]  I. Giaever,et al.  Micromotion of mammalian cells measured electrically. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[18]  M. Marinus,et al.  MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA* , 2002, The Journal of Biological Chemistry.

[19]  S. Wölfl,et al.  Synthesis, biological activity, and structure-activity relationships for potent cytotoxic rhodium(III) polypyridyl complexes. , 2008, Journal of medicinal chemistry.

[20]  E. Åvall-Lundqvist,et al.  Ovarian carcinoma cells with low levels of β-F1-ATPase are sensitive to combined platinum and 2-deoxy-d-glucose treatment , 2009, Molecular Cancer Therapeutics.

[21]  S. Chaney,et al.  Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. , 2005, Critical reviews in oncology/hematology.

[22]  S. Wölfl,et al.  Ranking: a closer look on globalisation methods for normalisation of gene expression arrays. , 2002, Nucleic acids research.

[23]  Douglas A. Hosack,et al.  Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.

[24]  Jae Hyun Kim,et al.  Role of ERK activation in cisplatin‐induced apoptosis in OK renal epithelial cells , 2005, Journal of applied toxicology : JAT.

[25]  C. Chou,et al.  DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation , 2003, Oncogene.

[26]  Wei Wang,et al.  Coordination of the nuclear and cytoplasmic activities of p53 in response to DNA damage. , 2010, Biophysical journal.

[27]  Stefan Wölfl,et al.  Microarray‐based kinetic colorimetric detection for quantitative multiplex protein phosphorylation analysis , 2011, Proteomics.

[28]  B Wolf,et al.  Multiparametric microsensor chips for screening applications , 2001, Fresenius' journal of analytical chemistry.

[29]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.